Posted Mar. 3, 2017 at 12:11 p.m.

Durham-based Chimerix beats Wall Street expectations

Published: 2017-03-03 12:11:30
Updated: 2017-03-03 12:11:30

Chimerix Chimerix

Chimerix Inc., a pharmaceutical research company, exceeded Wall Street analysts’ expectations despite reporting a $15.4 million loss in the fourth quarter.

Durham-based Chimerix reported a net loss of 32 cents per diluted share, beating analysts’ estimates of a 39 cents loss per diluted share. During the same period in 2015, Chimerix suffered a loss of $38.2 million, or 82 cents per diluted share.

The pharmaceutical development group reported a fourth-quarter revenue of $2 million, beating the predicted revenue of $890,000.

For the year, Chimerix reported a net loss of $76.4 million, or $1.65 per diluted share, lower than the $117.4 million loss reported in 2015. Revenues for 2016 decreased to $5.7 million, compared to $10.8 million from the previous year.

Research and development expenses were $58.6 million for the year, lower than the $97.7 million reported in 2015. Loss from operations was $78 million, reduced from the $118.3 million reported last year.

Net interest income increased $700,000 from last year to $1.6 million.

Chimerix shares have climbed 25 percent since the beginning of the year, with stock increasing 17 percent in the last 12 months.

Chimerix shares closed at $5.97, up 20 cents, or 3.47 percent, on Thursday.

Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 The University of North Carolina at Chapel Hill. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders